Overview:
Management of biliary tract cancers (BTC) is rapidly evolving as novel and emerging biomarkers and molecular testing strategies are informing treatment for a more individualized and targeted approach. This live webcast brings together renowned experts in the treatment of biliary tract cancers. In this educational symposium, these experts will provide an update on state-of-the-art treatment with immunotherapy and targeted therapeutic approaches in advanced cholangiocarcinoma, including case-based discussion of current and emerging clinical trial data on immune-based and targeted therapeutic strategies, best practices for adverse event management, and personalized treatment planning. This program will help clinicians who care for patients with cholangiocarcinoma gain additional knowledge and competence needed to deliver optimal patient care.
Learning objectives:
Upon completion of this activity, participants should be better prepared to:
- Identify patients with advanced/metastatic biliary tract cancer (BTC) who may be candidates for treatment with immune checkpoint inhibitors
- Assess efficacy and safety data from clinical trials evaluating current and investigational immune-based therapies for patients with advanced/metastatic BTCs
- Develop proactive strategies for monitoring and managing potential immune-related adverse events in patients receiving immune checkpoint inhibitor therapies for BTC
- Incorporate immune-based therapies for appropriate patients with advanced/metastatic BTC by integrating biomarker testing, clinical trial evidence, expert guidelines, patient co-morbidities, and goals of treatment
Target Audience:
This educational activity is directed toward physicians and other allied healthcare professionals involved in the diagnosis, treatment, and management of biliary tract cancers.
Tanios Bekaii-Saab, MD, FACP
Professor of Medicine Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Consultant, Division of Hematology/Oncology
Mayo Clinic Cancer Center
Consortium Chair
Academic and Community Cancer Research United
Phoenix, AZ
Richard S. Finn, MD
Professor of Medicine, Department of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Santa Monica, CA
Eugene J. Koay, MD
Associate Professor, Department of Radiation Oncology
Division of Radiation Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Aiwu Ruth He, M.D., Ph.D.
MedStar Georgetown University Hospital
GI Oncology
Scientific Lead in Liver & Biliary Cancers
Washington, DC
Time | Topic | Faculty |
1:30 PM | Welcome, Introductions, and Pre-session Survey | Tanios Bekaii-Saab, MD |
1:40 PM | Diagnosing and Managing Biliary Tract Cancers: State of the Art in 2024 | Eugene J. Koay, MD, PhD |
1:55 PM | Current and Emerging Data with Immune-Based Therapies in Biliary Tract Cancers and Cases (4) | Richard S. Finn, MD Eugene J. Koay, MD, PhD Aiwu Ruth He, M.D., Ph.D. |
2:30 PM | Managing Immune-Related Adverse Events and Case (1) | Richard S. Finn, MD Eugene J. Koay, MD, PhD Aiwu Ruth He, M.D., Ph.D. |
3:00 PM | Audience Q&A, Post-Test, and Concluding Remarks | Tanios Bekaii-Saab, MD |
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
